EUCTR2021-002006-27-FR进行中（未招募）1 期
A randomized, double-blind, placebo -controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT) - Study of inclisiran to prevent cardiovascular (CV) events in participants with established cardiovas
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 15,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or female =40 years of age
- •- Fasting LDL-C =1.8 mmol/L (70 mg/dL) at the Screening Visit
- •- At the Screening Visit, participants must be on a stable (=4 weeks) and well-tolerated lipid-lowering regimen (including e.g. with or without Ezetimibe) that must include a high-intensity statin therapy with either atorvastatin =40 mg QD or rosuvastatin =20 mg QD
- •- Established CV disease, defined as any of the following:
- •- Previous myocardial infarction
- •- Previous ischemic stroke
- •- Symptomatic peripheral arterial disease (PAD), as evidenced by either intermittent claudication with ABI <0.85, prior peripheral arterial revascularization procedure, or, amputation due to atherosclerotic disease
- •Other inclusion criteria are listed in the clinical study protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 9000
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 6000
排除标准
- •- New York Heart Association (NYHA) class III or IV heart failure at the Statin Optimization Screening Visit (if applicable), Screening Visit, or at the Baseline Visit (Day1)
- •- Previous exposure to inclisiran or any other non-mAb PCSK9-targeted therapy, either as an investigational or marketed drug within 2 years prior to the first study visit
- •- Pregnant or nursing (lactating) women
- •- Women of child-bearing potential, unless they are using effective methods of contraception during dosing of study treatment
- •Other exclusion criteria are listed in the clinical study protocol.
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR® Depot and RAD001 10 mg/d or Sandostatin LAR® Depot and placebo - N/Aow grade neuroendocrine carcinoma consists of carcinoid and pancreatic endocrine tumors. These tumors originate from the neuroendocrine cells throughout the body and are capable of producing various peptides. Their clinical course is often indolent but can also be highly aggressive and resistant to therapy. Current treatments for bulky metastatic tumors have either low biologic activity, high unfavorable toxicity profile or both.MedDRA version: 8.1Level: LLTClassification code 10007276Term: Carcinoid tumour NOSEUCTR2006-004507-18-FIovartis Pharma Services AG390
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, multicenter parallel-group dose ranging clinical trial to assess the efficacy and safety of Org 4419-2 in the treatment of obstructive sleep apnea/hypopnea syndromeEUCTR2005-000733-37-SEV Organon100
进行中（未招募）
1 期
A trial to learn more about how BAY 2327949 works and how safe it is in participants with chronic kidney diseaseMedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersChronic Kidney DiseaseEUCTR2020-002192-35-FIBayer - AG120
进行中（未招募）
1 期
Clinical Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS)Amyotrophic lateral sclerosis (ALS)MedDRA version: 14.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-022818-19-BEBiogen Idec Limited915
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, multicenter, two-part, dose ranging and confirmatory study with an operationally seamless design, evaluating efficacy and safety of SAR153191 on top of methotrexate (MTX) in patients with active rheumatoid arthritis who are inadequate responders to MTX therapy - MOBILITYMedDRA version: 12.0Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2009-016266-90-CZSanofi-aventis Recherche & Développement1,740